The push follows the patent expiry of semaglutide, which set off a rush of cheaper generics, but also exposed regulatory gaps—particularly in digital pharmacies and clinics.
Nordisk’s India managing director told ThePrint, his company has now moved to higher-dose Semaglutide, oral formulations and two new therapies which are advancing as cardiometabolic care.
Tirzepatide is the active ingredient in Lilly’s popular anti-obesity & diabetes drugs, Mounjaro & Zepbound. Experts say the matter has little relevance for India at present.
Several leading Indian drugmakers have already secured regulatory approval or recommendations to produce and market generic versions of the weight loss drugs in India.
Pharma firms are pouncing on opportunity as patents on world’s second-bestselling drug, which goes by brand names Ozempic and Wegovy, are expiring in nearly 100 nations.
Both medications were prescribed as weekly injections for patients clinically classified as obese, and were recommended alongside a controlled diet and regular physical activity.
India’s obesity crisis fuels a $2.6 bn drug race as pharma firms rush to launch affordable semaglutide generics, aiming to transform access to weight-loss treatment.
Desperation for ‘weight-loss’ drug that’s used to treat type-2 diabetes is real. Break-ins at pharmacies have also been reported in Michigan, US, and Santiago de Copostela, Spain.
Weight-loss drugs helped Dimpy Kapoor shed 15 kg and reclaim her life. Ozempic and Mounjaro are a lifeline for diabetics and the obese, but everyone wants in—even those who don’t need them.
While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its effectiveness in obesity management come out in 3 months.
Rather than functioning as conventional propaganda, the video operates as a device for interpretation, subtly shaping expectations about future developments in China’s naval trajectory.
By pairing Indian drone engineering with Japanese semiconductor expertise, the two firms aim to develop more advanced autonomous systems tailored to both defence & commercial use.
American objectives are unmet. They neither have muscle nor motivation to resume the war. As for Iran, the regime didn’t just survive, it’s now led by more radical individuals.
COMMENTS